Circulating Inflammatory Biomarkers Level before Thrombolysis for Acute Ischemic Stroke Predicts Symptomatic Intracerebral Hemorrhage

Recombinant tissue plasminogen activator (rtPA) remains the only therapeutic agent approved for salvaging the penumbra through reperfusion after acute ischemic stroke (AIS) [1]. It effectively dissolves thrombi within 4.5 h after stroke onset, but it increases the risk of cerebral hemorrhage and malignant cerebral edema in AIS patients [2]. Thrombosis and inflammation are highly intertwined contributors to the pathophysiologic processes of stroke.